6 completed, 1 unknown. 4 Phase 2, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow octenidine: new trials by email Literature Review of octenidine trials Research Report on octenidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Using Octenidine Hydrochloride as a Final Irrigation Solution on Teeth With Asymptomatic Apical Periodontitis on Postoperative Pain and Treatment Success: A Prospective Randomized Clinical Study Octenidine dihydrochloride 0.1%, Chlorhexidine 2% - Apical Periodontitis, Postoperative Pain | Not applicable | Completed | Bezmialem Vakif University | 142 | 2023-03-08 | 2025-09-15 |
| Skin Microbiome and Polymorphic Light Eruption Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) - Polymorphic Light Eruption | Not applicable | Unknown | Medical University of Graz | 30 | 2021-05-07 | 2021-08-02 |
| Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo Octenidine dihydrochloride, Placebo - Gingivitis | Phase 2 | Completed | Schülke & Mayr GmbH | 90 | 2013-10-01 | 2014-05-14 |
| Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis LAS41003, LAS189961, LAS189962 - Tinea Pedis | Phase 2 | Completed | Almirall, S.A. | 120 | 2010-02-01 | 2012-07-09 |
| Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections LAS41003, LAS189962, LAS189961 - Candidiasis | Phase 2 | Completed | Almirall, S.A. | 137 | 2010-02-01 | 2012-07-04 |
| Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema LAS41003, LAS189962, LAS189961 - Eczema | Phase 2 | Completed | Almirall, S.A. | 150 | 2009-11-01 | 2010-07-09 |
| Prevention of Catheter-Associated Infection With the Skin Disinfectant Octenidine Dihydrochloride 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol, 74% Ethanol with 10% 2-propanol - Catheterization, Central Venous, Catheter-Associated Infections | Phase 4 | Completed | University Hospital Freiburg | 400 | 2002-05-01 | 2007-08-13 |
Bacteremia (1) · Bacterial Infections (1) · Candidiasis (1) · Catheter-Related Infections (1) · Eczema (1) · Gingivitis (1) · Pain, Postoperative (1) · Periapical Periodontitis (1) · Sepsis (1) · Tinea Pedis (1)
Almirall, S.A. (3) · Bezmialem Vakif University (1) · Medical University of Graz (1) · Schülke & Mayr GmbH (1) · University Hospital Freiburg (1)
Germany (5) · Austria (1) · Switzerland (1) · Turkey (Türkiye) (1)
Christoph Willers, MD, MBA (3) · Katrin Lorenz, Dr. (1) · Markus Dettenkofer, Prof. MD (1) · Peter Wolf, MD (1)
2009 (2)